Unlocking New Paths with Smart Peptides
SPIMA Therapeutics Develops Smart Peptide-Based Immunotherapies to Address Undruggable Targets
We aim at bringing to patients innovative medicines treating diseases
with challenging immunological avenues
About SPIMA Therapeutics
SPIMA Therapeutics emerges as a spin-off from the University of Montpellier, France, uniting experts in cutting-edge peptide chemistry and inflammation biology.
SPIMA focuses on developing innovative peptide-based immunotherapies for challenging targets, particularly protein-protein interactions. Our lead program is a Stapled Peptide targeting the Myddosome complex. This innovative approach holds immense promise for revolutionizing treatments in inflammatory and oncological diseases, offering hope where it's needed most.
SPIMA Therapeutics is part of the nexus of Landmark Bioventures.
Join us in shaping the future of medicine, where discovery meets dedication.
Our Technology
Locking peptides into their bioactive α-helical conformation through site-specific introduction of a chemical brace
Our technology is centered on constraining short chains of amino acids — polypeptides — in a specific folded shape known as an α-helical conformation, which confers upon them unique drug-like properties including enhanced membrane permeability and stability
This makes Stapled Peptides promising candidates for intracellular protein-protein drug targeting
Our Pipeline
Co-Founders - Executive Team
Mohamed Haitham Ayad RPh, PhD
Chief Executive Officer